Literature DB >> 23619463

Establishment and characterization of novel cell lines and xenografts from patients with gastrointestinal stromal tumors.

Kazumasa Fukuda1, Yoshiro Saikawa, Hiroyuki Sako, Yumi Yoshimura, Tsunehiro Takahashi, Norihito Wada, Hirohumi Kawakubo, Hiroya Takeuchi, Tai Ohmori, Yuko Kitagawa.   

Abstract

At present, no suitable GIST model exists for the analysis of drug resistance or metastasis using established human gastrointestinal stromal tumor (GIST) cell lines or xenografts even though the molecular mechanisms of drug resistance, progression and metastasis require clarification. The aim of this study was to establish and characterize human GIST cell lines and xenografts that can be used for evaluating drug resistance or various new molecularly targeted therapies. GIST tissues from patients were cultured and implanted under the skin of NOG (NOD/Shi-scid, IL-2Rrnu) mice. Two new cell lines (GK1C and GK3C) and three xenografts (GK1X, GK2X and GK3X) were generated from these clinical samples. The established GIST cell lines and xenografts were investigated for tumorigenesis and imatinib sensitivity. These cell lines and xenografts showed characteristic GIST morphology and exhibited KIT expression profiles similar to those of the patient samples. In addition, these GIST cell lines and xenografts were sensitive to imatinib. In conclusion, new human GIST cell lines and xenografts were established and maintained through repeated passages. These models will enable further study of combination therapies and the mechanisms of resistance, and allow testing of novel targeted monotherapies and combination therapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23619463     DOI: 10.3892/or.2013.2425

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  1 in total

1.  Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells.

Authors:  Hiroyuki Sako; Kazumasa Fukuda; Yoshiro Saikawa; Rieko Nakamura; Tsunehiro Takahashi; Norihito Wada; Hirohumi Kawakubo; Hiroya Takeuchi; Tai Ohmori; Yuko Kitagawa
Journal:  PLoS One       Date:  2014-09-15       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.